Premium
Outcome of cervix uteri cancer patients: Clinical treatment results and toxicity profile in a retrospective study from Saudi Arabia
Author(s) -
El Sayed Mohamed E,
Bahadur Yasir A,
Hassouna Ashraf H,
Fawzy Ehab E,
Nasr Azza M,
Sadiq Bakr B,
Dada Reyad,
Sait Khalid H,
Anfinan Nisrin M
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12486
Subject(s) - medicine , cervix , stage (stratigraphy) , cervical cancer , retrospective cohort study , gastroenterology , brachytherapy , radiation therapy , cancer , urology , oncology , gynecology , paleontology , biology
Aim This study evaluated the survival outcome, pattern of failure and prognostic factors in cervix uteri cancer patients. Methods We reviewed the data of 60 patients with stages IB‐IVA cancer who were treated between January 2004 and December 2010. Results Most patients ( n = 50; 83%) had squamous cell carcinoma. Stage IIB was the most common presentation ( n = 41; 68%). Forty‐seven patients (78%) received Cisplatin concurrent with radiotherapy (CRT). The 2‐ and 4‐year overall survival (OS) was 82% and 79%, respectively. Prolongation of the overall treatment time (OAT) for greater than 56 days, advanced stage and pretreatment hemoglobin (Hb) levels (<10 g/dL) negatively predicted OS ( P = 0.039, P = 0.044 and P = 0.008, respectively). The 2‐ and 4‐year disease‐free survival (DFS) rates were 80% and 69%, respectively. Vaginal infiltration and brachytherapy (orthogonal versus CT‐based planning) were significant factors for the prediction of relapse ( P = 0.048 and P = 0.049, respectively). The 2‐ and 4‐year loco‐regional control (LRC) rates were 78% and 70%, respectively, and the distant metastasis‐free survival (DMFS) rates were 82% and 79%, respectively. Vaginal infiltration was the only negative predictive factor for LRC ( P = 0.045), and pathological tumor grade was the only factor indicative of distant metastases ( P = 0.037). Grade 3 or 4 late rectal reactions were reported in two patients (3%), and no patients developed grade 3 or 4 urinary reactions. Conclusion The treatment results in our cervix uteri cancer patients and the prognostic factors are comparable to those of previous reports. Orthogonal brachytherapy planning and vaginal infiltration negatively predicted relapse.